Blue Owl Capital Holdings LP
Long book
$372.2M
Q1 2026
Positions
75
Top-10 weight
69%
concentration
Last quarter
+8.8%
SPY +14.8%
Turnover
45%
of book per quarter
Strategy in plain words
auto-generated from filingsBlue Owl Capital Holdings LP is a diversified fundamental manager, specialised in healthcare (89% of the long book), running a $372.2M US long book across 75 positions.
The portfolio is concentrated: the top 10 names carry 69% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: AKTIS ONCOLOGY INC, LARIMAR THERAPEUTICS INC, enGene Therapeutics Inc, NUVEEN CHURCHILL DIRECT LEND, CULLINAN THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 3.3pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-10.6%
Q2 2024
+5.0%
Q3 2024
-3.8%
Q4 2024
-24.2%
Q1 2025
+7.6%
Q2 2025
+14.5%
Q3 2025
+10.7%
Q4 2025
+2.6%
Q1 2026
+8.8%
Sector allocation
Healthcare 77%
Other 15%
Industrials 4%
Services media 3%
Technology 1%
Financials 0%
Utilities 0%
Consumer discretionary 0%
Long book by quarter
What does Blue Owl own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| AKTS AKTIS ONCOLOGY INC | Healthcare | 3.2M | $56.6M | 15.2% | New |
| LRMR LARIMAR THERAPEUTICS INC | Healthcare | 7.1M | $32.0M | 8.6% | +4.3% |
| ENGN enGene Therapeutics Inc | Healthcare | 4.4M | $30.1M | 8.1% | +31.4% |
| NCDL NUVEEN CHURCHILL DIRECT LEND | — | 2.1M | $27.3M | 7.3% | Held |
| CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.9M | $27.1M | 7.3% | -18.8% |
| OBDC BLUE OWL CAPITAL CORP | — | 2.0M | $22.6M | 6.1% | Held |
| MPLT MAPLIGHT THERAPEUTICS INC | Healthcare | 1.0M | $20.5M | 5.5% | +207.6% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 2.9M | $15.6M | 4.2% | -15.1% |
| CNTX CONTEXT THERAPEUTICS INC | Healthcare | 5.1M | $13.3M | 3.6% | -31.5% |
| HLLY HOLLEY INC | Industrials | 4.2M | $13.0M | 3.5% | +2.2% |
| EYPT EYEPOINT INC | Healthcare | 912.6K | $11.8M | 3.2% | +132.5% |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 545.0K | $8.0M | 2.1% | New |
| CNDT CONDUENT INC | Services media | 5.0M | $6.4M | 1.7% | +4.4% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 302.6K | $6.3M | 1.7% | +42.3% |
| AQST AQUESTIVE THERAPEUTICS INC | Healthcare | 1.3M | $5.6M | 1.5% | +156.7% |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 61.5K | $5.3M | 1.4% | New |
| CMPS COMPASS PATHWAYS PLC | Healthcare | 1.8M | $5.1M | 1.4% | New |
| IMMX IMMIX BIOPHARMA INC | Healthcare | 547.6K | $5.0M | 1.3% | -44.5% |
| IMA IMAGENEBIO INC | Healthcare | 959.3K | $4.8M | 1.3% | +16.5% |
| CVEO CIVEO CORP | Services media | 180.5K | $4.8M | 1.3% | -51.3% |
| LENZ LENZ THERAPEUTICS INC | Healthcare | 506.7K | $4.6M | 1.2% | +237.8% |
| ELDN ELEDON PHARMACEUTICALS INC | Healthcare | 1.4M | $4.4M | 1.2% | -26.4% |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 215.0K | $4.3M | 1.2% | -40.3% |
| OVID OVID THERAPEUTICS INC | Healthcare | 1.9M | $4.2M | 1.1% | New |
| PVLA PALVELLA THERAPEUTICS INC | Healthcare | 31.3K | $3.9M | 1.0% | -22.4% |
| PLRX PLIANT THERAPEUTICS INC | Healthcare | 3.0M | $3.7M | 1.0% | Held |
| ADCT ADC THERAPEUTICS SA | Healthcare | 733.6K | $2.6M | 0.7% | Held |
| EVMN EVOMMUNE INC | Healthcare | 100.0K | $2.3M | 0.6% | New |
| DELL DELL TECHNOLOGIES -C | Technology | 13.9K | $2.3M | 0.6% | -74.2% |
| LRMR LARIMAR THERAPEUTICS INC | Healthcare | 975.7K | $1.9M | 0.5% | New |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 150.0K | $1.9M | 0.5% | -70.9% |
| SGMT SAGIMET BIOSCIENCES INC-A | Healthcare | 333.9K | $1.7M | 0.5% | -73.2% |
| WW WW INTERNATIONAL INC-NEW | Services media | 95.6K | $1.3M | 0.4% | New |
| ENGN enGene Therapeutics Inc | Healthcare | 511.2K | $1.3M | 0.3% | +1316.0% |
| EPD ENTERPRISE PRODUCTS PARTNERS | Utilities | 31.3K | $1.2M | 0.3% | Held |
| FLD FOLD HOLDINGS INC | Financials | 856.6K | $1.1M | 0.3% | Held |
| MRKR MARKER THERAPEUTICS INC | Healthcare | 554.3K | $721K | 0.2% | Held |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 200.0K | $590K | 0.2% | New |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 400.0K | $500K | 0.1% | New |
| CAH CARDINAL HEALTH INC | Consumer discretionary | 1.7K | $363K | 0.1% | Held |
| PIPR PIPER SANDLER COS | Financials | 2.4K | $186K | 0.0% | New |
| AMOD ALPHA MODUS HOLDINGS INC | Financials | 394.1K | $146K | 0.0% | Held |
| ET ENERGY TRANSFER LP | Utilities | 5.3K | $103K | 0.0% | New |
| DAIC CID HOLDCO INC | Technology | 557.4K | $95K | 0.0% | Held |
| CAI CARIS LIFE SCIENCES INC | Healthcare | 4.7K | $84K | 0.0% | New |
| VKTX VIKING THERAPEUTICS INC | Healthcare | 50.0K | $68K | 0.0% | New |
| SHFS SHF HOLDINGS INC | Financials | 75.9K | $63K | 0.0% | Held |
| GOCOQ GOHEALTH INC-CLASS A | Financials | 40.8K | $62K | 0.0% | New |
| AEON AEON BIOPHARMA INC | Healthcare | 42.4K | $42K | 0.0% | -2.4% |
| GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 100.0K | $25K | 0.0% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 76 | $372.2M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR/ARESTATEMENT | Feb 20, 2026 | 83 | $324.0M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 9, 2026 | 83 | $1.34B | SEC ↗ | |
| Q3 2025 | 13F-HR | Nov 12, 2025 | 75 | $322.1M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 11, 2025 | 73 | $309.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 74 | $310.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 80 | $433.7M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 141 | $514.0M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 15, 2024 | 43 | $359.6M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 49 | $500.6M | canonical | SEC ↗ |